It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNKK advanced for three days, in 185 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
BNKK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
BNKK moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNKK crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNKK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNKK entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.297) is normal, around the industry mean (-3.208). P/E Ratio (-0.047) is within average values for comparable stocks, (26.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.732). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.923) is also within normal values, averaging (2.785).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. BNKK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNKK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.
The RSI Oscillator for CPIX moved out of oversold territory on October 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 17 of the 18 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CPIX as a result. In 93 of 110 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CPIX just turned positive on November 11, 2026. Looking at past instances where CPIX's MACD turned positive, the stock continued to rise in 50 of 58 cases over the following month. The odds of a continued upward trend are 86%.
Following a +25.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CPIX advanced for three days, in 177 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 44 cases where CPIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
CPIX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CPIX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CPIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
CPIX broke above its upper Bollinger Band on November 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CPIX entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CPIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.485) is normal, around the industry mean (6.379). P/E Ratio (-7.151) is within average values for comparable stocks, (0.548). CPIX's Projected Growth (PEG Ratio) (17.640) is very high in comparison to the industry average of (2.202). CPIX's Dividend Yield (1.149) is considerably higher than the industry average of (0.062). P/S Ratio (2.362) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BNKK | CPIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 51 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | 42 | |
P/E GROWTH RATING 1..100 | 26 | 17 | |
SEASONALITY SCORE 1..100 | 13 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNKK's Valuation (38) in the null industry is in the same range as CPIX (51) in the Pharmaceuticals Other industry. This means that BNKK’s stock grew similarly to CPIX’s over the last 12 months.
CPIX's Profit vs Risk Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for BNKK (100) in the null industry. This means that CPIX’s stock grew somewhat faster than BNKK’s over the last 12 months.
CPIX's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as BNKK (100) in the null industry. This means that CPIX’s stock grew similarly to BNKK’s over the last 12 months.
CPIX's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for BNKK (86) in the null industry. This means that CPIX’s stock grew somewhat faster than BNKK’s over the last 12 months.
CPIX's P/E Growth Rating (17) in the Pharmaceuticals Other industry is in the same range as BNKK (26) in the null industry. This means that CPIX’s stock grew similarly to BNKK’s over the last 12 months.
| BNKK | CPIX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 85% |
| MACD ODDS (%) | N/A | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| Advances ODDS (%) | 10 days ago 83% | 7 days ago 83% |
| Declines ODDS (%) | 2 days ago 90% | 3 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 78% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNKK’s FA Score shows that 1 FA rating(s) are green while CPIX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNKK’s TA Score shows that 4 TA indicator(s) are bullish while CPIX’s TA Score has 4 bullish TA indicator(s).
BNKK (@Beverages: Non-Alcoholic) experienced а -27.16% price change this week, while CPIX (@Pharmaceuticals: Generic) price change was +9.43% for the same time period.
The average weekly price growth across all stocks in the @Beverages: Non-Alcoholic industry was -2.36%. For the same industry, the average monthly price growth was +17.49%, and the average quarterly price growth was -8.45%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.76%. For the same industry, the average monthly price growth was -7.25%, and the average quarterly price growth was -8.78%.
BNKK is expected to report earnings on Nov 18, 2026.
Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.
@Pharmaceuticals: Generic (-4.76% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that BNKK and PBH have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNKK and PBH's prices will move in lockstep.
| Ticker / NAME | Correlation To BNKK | 1D Price Change % | ||
|---|---|---|---|---|
| BNKK | 100% | -11.86% | ||
| PBH - BNKK | 23% Poorly correlated | +0.46% | ||
| REED - BNKK | 22% Poorly correlated | N/A | ||
| CPIX - BNKK | 21% Poorly correlated | +11.32% | ||
| SNDL - BNKK | 21% Poorly correlated | N/A | ||
| HNNA - BNKK | 21% Poorly correlated | +0.70% | ||
More | ||||
A.I.dvisor tells us that CPIX and ACB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPIX and ACB's prices will move in lockstep.
| Ticker / NAME | Correlation To CPIX | 1D Price Change % | ||
|---|---|---|---|---|
| CPIX | 100% | +11.32% | ||
| ACB - CPIX | 27% Poorly correlated | -1.95% | ||
| QNTM - CPIX | 26% Poorly correlated | +10.42% | ||
| YCBD - CPIX | 23% Poorly correlated | +0.28% | ||
| PRGO - CPIX | 22% Poorly correlated | -2.60% | ||
| LFCR - CPIX | 22% Poorly correlated | -0.39% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| YANG | 35.02 | 1.31 | +3.89% |
| Direxion Daily FTSE China Bear 3X ETF (YANG) | |||
| GLGG | 1.86 | N/A | N/A |
| Leverage Shares 2X Long GLXY Daily ETF (GLGG) | |||
| FMAY | 55.69 | -0.50 | -0.89% |
| FT Vest U.S. Equity Buffer Fund - May (FMAY) | |||
| BREE | 24.04 | -0.26 | -1.07% |
| MFS Blended Research Emerging Markets Equity ETF (BREE) | |||
| DIVZ | 37.49 | -0.44 | -1.17% |
| Polen Dividend Income ETF (DIVZ) | |||